Peptide binding α1α2 domain of HLA-B27 contributes to the disease pathogenesis in transgenie mice

Human Immunology

Volumn 60, Issue 2, 1999, Pages 116-126

  Khare, Sanjay D ^a   Lee, Sonwoo ^a   Bull, Michael J ^a   Hanson, Julie ^a   Luthra, Harvinder S ^b   Hammerling, Gunther J ^c   David, Chella S ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

HLA B27; Reactive arthritis; Reiter's disease; Spondyloarthropathies; Transgenic animal model

Indexed keywords

HLA B27 ANTIGEN; BETA 2 MICROGLOBULIN; H 2K(K) ANTIGEN; H-2K(K) ANTIGEN; H2 ANTIGEN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTHRITIS; ARTICLE; CONTROLLED STUDY; HLA SYSTEM; IMMUNOPATHOGENESIS; MOUSE; NAIL DISEASE; NONHUMAN; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; TRANSGENIC MOUSE; ANIMAL; BINDING SITE; BIOSYNTHESIS; CELL MEMBRANE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; BETA 2-MICROGLOBULIN; BINDING SITES; CELL MEMBRANE; H-2 ANTIGENS; HLA-B27 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; PEPTIDES;

EID: 0032587504     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(98)00104-9     Document Type: Article

References (40)

1. Schlosstein L., Terasaki P.I., Bluestone R., Pearson C.M. High association of an HLA antigen, w27, with ankylosing spondylitis. N Engl J Med. 288:1973;704.
2. Brewerton D.A., Hart F.D., Nicholls A., Caffrey M., James D.C., Sturrock R.D. Ankylosing spondylitis and HL-A 27. Lancet. i:1973;904.
3. Khan M.A. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin N Am. 18:1992;1.
4. Burmester G.R., Daser A., Kamradt T., Krause A., Mitchison N.A., Sieper J., Wolf N. Immunology of reactive arthritides. Ann Rev Immunol. 13:1995;229.
5. 2m An animal model of HLA-B27 associated human disorders . Cell. 63:1990;1099.
6. 2-microglobulin a model of human spondyloarthropathies . J Exp Med. 182:1995;1153.
7. Khare S.D., Hansen J., Luthra H.S., David C.S. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human b2-microglobulin double transgenic mice with disrupted mouse b2m. J Clin Invest. 98:1996;2746.
8. Taurog J.D., Richardson J.A., Croft J.T., Simmons W.A., Zhou M., Fernandez-Sueiro J.L., Balish E., Hammer R.E. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 180:1994;2359.
9. Geczy A.F., Alexander K., Bashir H.V., Edmonds J.P., Upfold L., Sullivan J.S. HLA-B27, Klebsiella and ankylosing spondylitis biological and chemical studies . Immunol Rev. 70:1983;23.
10. Khare S.D., Luthra H.S., David C.S. Role of HLA-B27 in spondyloarthropathies. Curr topics Microbiol Immunol. 206:1996;85.
11. Madden D.R., Gorga J.C., Strominger J.L., Wiley D.C. The three-dimensional structure of HLA-B27 at 2 1 A resolution suggests a general mechanism for tight peptide binding to MHC . Cell. 70:1992;1035.
12. Jardetzky T.S., Lane W.S., Robinson R.A., Madden D.R., Wiley D.C. Identification of self peptides bound to purified HLA-B27. Nature. 353:1991;326.
13. Scofield R.H., Warren W.L., Koelsch G., Harley J.B. A hypothesis for the HLA-B27 dysregulation in spondyloarthopathy contribution from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution . Proc Natl Acad Sci USA. 90:1993;9330.
14. Scofield R.H., Kurien B., Gross T., Warren W.L., Harley J.B. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria implications for spondyloarthropathies . Lancet. 345:1995;1542.
15. Boisgerault F., Tieng V., Stolzenberg M.-C., Dulphy N., Khalil I., Tamouza R., Charron D., Toubert A. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic varients. J Clin Invest. 98:1996;2764.
16. Garcia F., Marina A., Albar J.P., Lopez de Castro J.A. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens. 49:1997;23.
17. Sieper J., Kingsley G. Recent advances in the pathogenesis of reactive arthritis. Immunol Today. 17:1996;160.
18. Parhem P. Presentation of HLA class I-derived peptides potential involvement in allorecognition and HLA-B27-associated arthritis . Immunol Rev. 154:1997;137.
19. Westman P., Partanen J., Leirisalo-Repo M., Koskimies S. Different DRB1*04 alleles predominate in the Finnish random population and in HLA-B27-positive subpopulations. Tissue Antigens. 44:1994;327.
20. Tuokko J., Reijonen H., Ilonen J., Anttila K., Nikkari S., Mottonen T., Yli-Kerttula U., Toivanen A. Increase of HLA-DRB1*0408 and -DQB1*0301 in HLA-B27 positive reactive arthritis. Ann Rheum Dis. 56:1997;37.
21. Viner N.J., Bailey L.C., Life P.F., Bacon P.A., Gaston J.S.H. Isolation of Yersinia-specific T-cell clones from the synovial membrane and synovial fluid of a patients with reactive arthritis. Arthritis Rheum. 34:1991;1151.
22. Hermann E., Mayet W.J., Thomssen H., Sieper J., Poralla T., Meyer zum Buschenfelde K.H., Fleischer B. HLA-DP restricted Chlamydia trachomatis specific synovial fluid T cell clones in Chlamydia-induced Reiter's disease. J Rheumatol. 19:1992;1243.
23. Khare S.D., Bull M.J., Hansen J., Luthra H.S., David C.S. Spontaneous disease in HLA-B27 transgenic mice in independent of MHC class II molecules a direct role for B27 heavy chains and not B27 derived peptides . J Immunol. 160:1998;101.
24. Kalinke U., Arnold B., Hammerling G.J. Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 domain into HLA-B27. Nature. 348:1990;642.
25. Bieberich C., Scangos G., Tanaka K., Jay G. Regulated expression of a murine class I gene in transgenic mice. Mol Cell Biol. 6:1986;1339.
26. Wentworth P.A., Celis E., Crimi C., Stitely S., Hale L., Tsai V., Serra H.M., Guercio M.-F.D., Livingston B., Alazard D., Fikes J., Kubo R.T., Grey H.M., Chesnut R.W., Chisari F.V., Sette A. In vitro induction of primary, antigen-specific CTL from human peripheral mononuclear cells stimulated with synthetic peptides. Mol Immunol. 32:1995;603.
27. Stam N.J., Spits H., Ploegh H.L. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol. 137:1986;2299.
28. Koller B.H., Marrack P., Kappler J., Smithies O. Normal development of mice deficient in beta 2M, MHC class I protein and CD8+ T cells. Science. 248:1990;1227.
29. Rock K.L., Gramm C., Benacerraf B. Low temperature and peptides favor the formation of class I heterodimers on RMA-S cells at the cell surface. Proc Natl Acad Sci USA. 88:1991;4200.
30. 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I. J Exp Med. 179:1994;661.
31. Rock K.L., Gamble S., Rothstein L., Gramm C., Benacerraf B. Dissociation of beta 2-microglobulin leads to the accumulation of a substantial pool of inactive class I MHC heavy chains on the cell surface. Cell. 65:1990;611.
32. Ribaudo R.K., Margulies D.H. Polymorphism at position nine of the MHC class I heavy chain affects the stability of association with beta 2-microglobulin and presentation of a viral peptide. J Immunol. 155:1995;3481.
33. Ikeda M., Yamaguchi A., Khare S., David C., Marker Herman E., Yu D.T.Y. HLA-B27 Free heavy chains expressed on beta2M negative cells assume a peptide-presenting conformation. Arthritis Rheum. 39:1996;S297.
34. Joyce S., Nathenson S.G. Alloreactivity, antigen recognition and T-cell selection three diverse T-cell recognition problems with a common solution . Immunol Rev. 154:1996;59.
35. Madden D.R., Garboczi D.N., Wiley D.C. The antigenic identity of peptide-MHC complexes a comparison of the conformations of five viral peptides presented by HLA-A2 . Cell. 75:1993;693.
36. Khare S.D., Luthra H.S., David C.S. Unraveling the mystery of HLA-B27 association with human spondyloarthropathies using transgenic and knock out mice. Sem Immunol. 10:1998;15.
37. Reis e Sousa C., Germain R.N. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med. 182:1995;841.
38. Jondal M., Schirmbeck R., Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity. 5:1996;295.
39. Norbury C.C., Chambers B.J., Prescott A.R., Ljunggren H.G., Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol. 27:1997;280.
40. Mitchell D.A., Nair S.K., Gilboa E. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur J Immunol. 28:1998;1923.